International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud, and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Cardiac Pacemakers, Inc.(CPI), doing business as Guidant Cardiac Rhythm Management, manufactured implantable cardiac rhythm management devices, such as pacemakers and defibrillators. It also sold insulin pumps controlled by microprocessors and various equipments to regulate heart rhythm. In addition, Cardiac Pacemakers, Inc. developed therapies for the treatment of irregular heartbeats. The company was founded in 1971 and is based in St. Paul, Minnesota. Cardiac Pacemakers, Inc. operates as a subsidiary of Boston Scientific Corporation.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

Endece is a privately held biopharmaceutical company at the forefront of new discovery and development. Our library of proprietary compounds, invented and owned by ENDECE, was designed to stop disease by regulating specific biological pathways to stimulate a biological response for a gain of function. we focus on diseases whose treatment options are limited or non-existent, whose causes may not be well understood and whose clinical development paths are still undefined including multiple sclerosis (MS) and Alzheimer's disease.

Regenesance BV was founded in november, 2009 on groundbreaking research from the academic medical center. AMC researchers found that an innate part of the immune system (complement pathway) is activated after nerve damage to produce a lytic complex (called the membrane attack complex or MAC). Normally, the MAC attacks pathogens and helps remove tissue debris following trauma. However, AMC researchers learned that MAC can also damage nerves, particularly those attempting to regrow after injury. This work indicates that a variety of acute or chronic nervous system disorders may benefit from new therapies that strategically control MAC activation.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

TAPIC provides patent translation and patent search services.

KineMed is a biotechnology company that specializes in providing translational and personalized medicine. The company offers unparalleled insight into the complex biological processes underlying the root causes of disease. It uses the administration of stable (non-radioactive) isotopes to provide high-definition pharmacological measurements of disease activity and drug effects across a wide range of therapy areas, including diseases of the nervous system, metabolic and cardiovascular diseases, cancer, inflammation, and musculoskeletal diseases. It was founded in 2001 and headquartered in Emeryville, California.

Boston Scientific Neuromodulation Corp. offers implantable pain management devices for neuromodulation. The company is headquartered in Marlborough, MA.

CereGate GmbH engages in the development of software platform. It focuses on interfacing with the human brain through the technology. The company is headquartered in Hamburg, Germany.

NC Medical Research specializes in research, development and licensing of cell therapy drugs.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Mestex is one of the important clusters for innovative pharmaceutical industries and biotech companies in Europe. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.